Novocure announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration (FDA). The PMA application for LUNAR was submitted with a filing date of December 15, 2023, and is now under substantive review by the FDA. Novocure expects to receive a regulatory decision from FDA in second half 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.03 USD | +3.22% | +25.82% | +7.37% |
02/05 | NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue | MT |
02/05 | BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.37% | 1.73B | |
+73.50% | 12.41B | |
-19.26% | 7.87B | |
+2.40% | 6.37B | |
+3.66% | 5.81B | |
+11.89% | 5.36B | |
+37.45% | 4.92B | |
-19.73% | 4.02B | |
-35.58% | 2.43B | |
+0.74% | 2.02B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer